Studying early signs of immune problems in children
Part of Blood & lymphatic, Immune system & allergy, Skin clinical trials.
This study looks at children newly diagnosed with immune thrombocytopenia (ITP) or lupus (SLE) before they start treatment. Researchers want to understand how these conditions develop, which may lead to better care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 1 and 17 years old and weigh at least 15 pounds (7 kg).
- You have just been diagnosed with ITP or lupus, and have not started any treatment yet.
- Your ITP is not caused by another condition like a weak immune system, organ transplant, or cancer.
- You are not pregnant, breastfeeding, or planning to become pregnant.
- You and your parents agree to join the study and have signed a consent form.
- You are covered by a health insurance plan or social security.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at blood test antibodies to help confirm whether low platelet counts are caused by an autoimmune condition. It may help doctors better classify your type of low platelets and guide appropriate next steps.
This study looks at blood and immune system patterns in adults with primary immune thrombocytopenia (ITP) who are starting their first treatment. The goal is to better understand what’s happening in ITP, which may improve how future patients are cared for.
This study follows children aged 6-17 with immune thrombocytopenia (ITP) over time to better understand the condition and how it changes. It aims to learn more about ITP in children to improve future care.
This study looks back at medical records of people with newly diagnosed or persistent ITP (lasting up to 12 months) to understand how the condition is treated in real life. Anyone who received standard ITP treatments or none at all may be included.
This study looks at how a treatment called CD3xCD19 BiTE affects the immune system of children with lupus that hasn't gotten better with standard medicines. It uses leftover blood samples to learn more about why some children don't respond to usual treatments.
This trial studies whether a “dose-dense” rituximab schedule can help children and teens with newly diagnosed, high-risk immune thrombocytopenia (ITP). It aims to raise/maintain platelet counts and control bleeding, while carefully checking safety.
Hear when a new Immune Thrombocytopenic Purpura ( ITP ) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.